SOURCE: Agennix AG

Agennix AG

January 12, 2011 04:32 ET

Agennix AG Announces Data From Talactoferrin Phase II Trial in Severe Sepsis to Be Presented at 40th Critical Care Congress of the Society of Critical Care Medicine

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - January 12, 2011) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that new and more detailed data from a Phase II trial in severe sepsis with talactoferrin, an oral biologic therapy with immunomodulatory and antibacterial properties, will be presented at the 40th Critical Care Congress of the Society of Critical Care Medicine, to be held January 15-19, 2011 in San Diego, California. 

Talactoferrin-related presentations are as follows:

"Talactoferrin alfa reduces 3 and 6 month all-cause mortality in patients with severe sepsis," will be part of the oral session, "Infectious Disease-Sepsis," to be held on January 16, 2011, 3:00-5:00 PM.

"Talactoferrin may confer increased survival in patients with septic shock and systolic cardiac dysfunction," will be presented as a poster presentation in the Therapeutics-Drugs and Pharmacokinetics-2 category.

About talactoferrin
Talactoferrin is an oral biologic therapy with immunomodulatory and antibacterial properties, which is being studied for the treatment of cancer and severe sepsis. Talactoferrin has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer (NSCLC), as well as in severe sepsis. As a result of the promising results from Phase II studies, two Phase III trials with talactoferrin in NSCLC have been initiated. NSCLC is one of the most common types of cancer worldwide and the most frequent cause of cancer death. Agennix also plans to develop talactoferrin further for the treatment of severe sepsis and expects to initiate the Phase II portion of a Phase II/III trial in that indication in March/April 2011. Talactoferrin has been shown to be very well tolerated in these patient populations. 

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that the Company will move talactoferrin forward in development for severe sepsis in a timely manner, if at all, or that talactoferrin will ultimately be approved for sale in any indication in any country. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact Information

  • For further information, please contact:
    Agennix AG
    Barbara Mueller
    Manager, Investor Relations &
    Corporate Communications
    Phone: +49 (0)89 8565 2693
    ir@agennix.com

    In the U.S.:
    Laurie Doyle
    Senior Director, Investor Relations &
    Corporate Communications
    Phone: +1 609 524 5884
    laurie.doyle@agennix.com

    Additional media contact for Europe:
    MC Services AG
    Raimund Gabriel
    Phone: +49 (0)89 210 228 0
    raimund.gabriel@mc-services.eu

    Additional investor contact for Europe:
    Trout International LLC
    Lauren Williams
    Vice President
    Phone: +44 207 936 9325
    lwilliams@troutgroup.com